Deals channel feed – Endpoints News

Deals channel feed

J&J fronts $750M cash to grab a failed cancer drug that’s been repurposed as a powerful anti-inflammatory

6 years ago

RAPT signs on with struggling Hanmi for Asian entrance of cancer therapy aimed at 'charged tumors'

6 years ago

Astellas snags a gene therapy upstart with $3B buyout bid — inspiring forecasts of more M&A ahead

6 years ago

Baker Bros. places a $250M bet on a potential rival to Regeneron and Novartis — with a $1B-plus payoff on the line

6 years ago

Veloxis wins $1.3B buyout, and the new owner plans to follow up with new deals

6 years ago

Ex-Purdue CEO stands to earn a huge windfall in Novartis' buyout of the Medicines Co

6 years ago

‘Breakthrough’ bladder cancer drug spinout gets $570M to back launch of a new gene therapy in the US

6 years ago

Acquisitive Novartis bags PCSK9 player MedCo for $9.7B, setting up a flank attack on Sanofi, Regeneron and Amgen

6 years ago

Teaming up with NIH, ViiV buys into the next big thing in HIV: antibodies

6 years ago

Ahead of strategic update, new Sanofi CEO mulls options for consumer healthcare arm — reports

6 years ago

Brii Bio backs infectious disease startup while inking deal for its lead TB drug, doubling down on antibiotics

6 years ago

AbbVie scoops up option to license Harpoon's BCMA drug for $50M upfront as biotech partner preps PhI/II trial

6 years ago

Dicerna scores broad, 'rest of liver' deal with Novo Nordisk, bagging $225M in cash to hit some 30 targets with RNAi platform

6 years ago

Dutch diagnostics player Qiagen confirms buyout talks following report of Thermo Fisher's interest

6 years ago

Roche bags 'breakthrough' anti-fibrosis drug in $1.4B biotech buyout deal

6 years ago

Sarepta picks up a slate of preclinical gene therapy programs, seeding new StrideBio deal with $48M upfront

6 years ago

Allergan enlists Exicure in search of hair loss drugs with $25M upfront, doubling down on area dear to AbbVie

6 years ago

Takeda doubles down on Finch's microbiome insights, signing up for a second project in Crohn's disease

6 years ago

Merck buys a fledgling neurodegenerative biotech spawned by an old GSK discovery alliance. What’s up with that?

6 years ago

An Israeli biotech gambles on a failed drug, merging with troubled Menlo ahead of PhIII data

6 years ago

Biogen doubles down on biosimilars pact with Samsung Bioepis, bagging ophthalmology, anti-TNF drugs

6 years ago

Evotec and Vifor launch joint kidney disease venture

6 years ago

Eli Lilly, Boehringer Ingelheim revise prolific diabetes pact, firing all cylinders for blockbuster Jardiance franchise

6 years ago

Andy Plump teams with MD Anderson on the race to cell therapy 2.0 — and they’re already planning a pivotal

6 years ago

First page Previous page 96 97 9899100 101 102 Next page Last page